Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide and Liposomal Doxorubicin in Kaposi Sarcoma
NCT02659930Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2016
- Primary completion
- Jan 2028
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of pomalidomide in Kaposi sarcoma (KS), multicentric Castleman disease (MCD) and Kaposi sarcoma-associated herpesvirus inflammatory cytokine syndrome (KICS) (4 arms), sponsored by National Cancer Institute. Primary endpoints: Safety and Tolerability of Dose Combinations at 3 months and Pharmacokinetics of Combination Therapy. Started Jan 2016; status: active, not recruiting.
02
Drugs
pomalidomide
03
Conditions
Kaposi sarcoma (KS)multicentric Castleman disease (MCD)Kaposi sarcoma-associated herpesvirus inflammatory cytokine syndrome (KICS)
Beyond the preview
Go deeper on NCT02659930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659930.